Barclays analyst Glen Santangelo upgraded Phathom Pharmaceuticals (NASDAQ: PHAT) from Equalweight to Overweight with a price target of $18.00 (from ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE